The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Sign in to access this content
Sign InAscent Group LLC expanded its position in Johnson & Johnson (JNJ) by 7.2% during the fourth quarter. The investment firm now holds shares valued at approximately $14.07 million, reflecting growing institutional confidence in the healthcare giant. This move comes despite significant insider selling activity, which totaled over $7.36 million within the last 90 days. Market analysts currently maintain a "Moderate Buy" rating on the stock, citing strong commercial milestones and long-term potential. The consensus price target for JNJ stands at $237.57, suggesting a substantial upside from current market levels. Institutional rebalancing remains a key driver for the stock as investors weigh fundamental growth against recent insider transactions.